FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)

3 Months Ended

Mar. 31, 2022

Fair Value Disclosures [Abstract]

Schedule of financial instrument measured at fair value

	Fair Value Measurement at March 31, 2022
	Total		Level 1		Level 2		Level 3
Investment in term promissory note of Ault & Company, Inc. (“Ault & Company”) and other – a related party	$	2,653,000	$	-	$	-	$	2,653,000
Investment in common stock of Alzamend Neuro, Inc. (“Alzamend”) – a related party		8,729,000		8,729,000		-		-
Investments in marketable equity securities		16,158,000		16,158,000		-		-
Cash and marketable securities held in trust account		116,737,000		116,737,000		-		-
Investments in equity securities		37,091,000		-		-		37,091,000
Total assets measured at fair value	$	181,368,000	$	141,624,000	$	-	$	39,744,000

	Fair Value Measurement at December 31, 2021
	Total		Level 1		Level 2		Level 3
Investment in term promissory note of Ault & Company and other – a related party	$	2,842,000	$	-	$	-	$	2,842,000
Investment in common stock of Alzamend – a related party		13,230,000		13,230,000		-		-
Investments in marketable equity securities		40,380,000		40,380,000		-		-
Cash and marketable securities held in trust account		116,725,000		116,725,000		-		-
Investments in equity securities		30,482,000		-		-		30,482,000
Total assets measured at fair value	$	203,659,000	$	170,335,000	$	-	$	33,324,000

Schedule of other equity securities measured and carried at fair value

	Investments in equity securities
Balance at January 1, 2022	$	30,482,000
Investment in equity securities		3,820,000
Change in fair value of warrants		10,281,000
Unrealized gains on equity securities		3,180,000
Conversion to marketable securities		(10,672,000	)
Balance at March 31, 2022	$	37,091,000